CD38 Targeting Holds Potential for the Treatment of Aggressive Refractory Cutaneous T-Cell Lymphomas. Pavlova O, Tsai YC, Chang YT, Vonow Eisenring M, et al. J Invest Dermatol 2023 Mar 16:S0022-202X(23)00107.

Read + Share

Amedeo Smart

Independent Medical Education

Pavlova O, Tsai YC, Chang YT, Vonow Eisenring M, et al. CD38 Targeting Holds Potential for the Treatment of Aggressive Refractory Cutaneous T-Cell Lymphomas. J Invest Dermatol 2023 Mar 16:S0022-202X(23)00107.
PMID: 36933969